ClinicalTrials.gg
CompletedNCT00206219Updated Jan 27, 2011

Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)

A Phase 3 interventional study of Gefitinib and methotrexate in Squamous Cell Carcinoma of the Head and Neck, sponsored by AstraZeneca. Completed at 110 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
477
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca — 4 open to participants now, 6 under way, 2 of them phase 3. Squamous Cell Carcinoma of Head and Neck · AstraZeneca.

Enrollment
3rd of 21
477 · median 78
Started
2003
with 1 other
Phase 3
4 of 22
1 open now
Registered
1st of 22
by date

Among the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2003, is one of 4 in phase 3, and was the 1st registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

4 of the 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Squamous Cell Carcinoma of Head and Neck by AstraZeneca, or all of them as a file.
02

Study summary

This study is to compare ZD1839 (250mg and 500mg) versus methotrexate in head and neck cancer in terms of overall survival.

03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck

Keywords

  • Squamous cell carcinoma of the head and neck
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological confirmation of evidence of squamous cell carcinoma of the head and neck.
  • Tumors have progressed after primary treatment with radiation or chemoradiation and have failed to respond to at least one course of standard platinum-based chemotherapy.
  • Tumors have progressed after primary treatment with radiation or chemoradiation and are considered unsuitable for platinum-based chemotherapy.

Exclusion criteria

Exclusion Criteria:

  • Carcinomas of the post-nasal space, thyroid, sinus or salivary gland tumors.
  • Isolated recurrent disease that may be amenable to local therapy; e.g., surgical intervention or radiation therapy.
  • Known severe to ZD1839, Methotrexate or any of the of these products.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
477 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Compare ZD1839 versus methotrexate in overall survival

Secondary outcomes

  1. Compare ZD1839 versus methotrexate in symptom improvement, tumor response, safety and tolerability and quality of life - assessed throughout the study.

07

Study locations

110 sites
  • Research Site
    Birmingham, Alabama, United States
  • Research Site
    Tucson, Arizona, United States
  • Research Site
    Palm Springs, California, United States
  • Research Site
    Aurora, Colorado, United States
  • Research Site
    New Haven, Connecticut, United States
  • Research Site
    Norwalk, Connecticut, United States
  • Research Site
    Miami, Florida, United States
  • Research Site
    Orlando, Florida, United States
  • Research Site
    Ormand Beach, Florida, United States
  • Research Site
    Savannah, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Des Moines, Iowa, United States
  • Research Site
    Louisville, Kentucky, United States
  • Research Site
    Baton Rouge, Louisiana, United States
  • Research Site
    Waterville, Maine, United States
  • Research Site
    Bethesda, Maryland, United States
  • Research Site
    Detroit, Michigan, United States
  • Research Site
    Omaha, Nebraska, United States
  • Research Site
    Hackensack, New Jersey, United States
  • Research Site
    Brooklyn, New York, United States
  • Research Site
    New York, New York, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Norfolk, Virginia, United States
  • Research Site
    Olympia, Washington, United States
  • Research Site
    Milwaukee, Wisconsin, United States
  • Research Site
    Capital Federal, Buenos Aires, Argentina
  • Research Site
    El Palomar, Buenos Aires, Argentina
  • Research Site
    Salta, Argentina
  • Research Site
    Santa Fe, Argentina
  • Research Site
    Westmead, New South Wales, Australia
  • Research Site
    Brussels (Woluwé-St-Lambert), Belgium
  • Research Site
    Brussels, Belgium
  • Research Site
    Edegem, Belgium
  • Research Site
    Gent, Belgium
  • Research Site
    Haine-Saint-Paul, Belgium
  • Research Site
    Goiânia, GO, Brazil
  • Research Site
    Rio de Janeiro, RJ, Brazil
  • Research Site
    São Paulo, SP, Brazil
  • Research Site
    Vancouver, British Columbia, Canada
  • Research Site
    Winnipeg, Manitoba, Canada
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Windsor, Ontario, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Research Site
    Zagreb, Croatia
  • Research Site
    Brno, Czech Republic
  • Research Site
    Ostrava - Poruba, Czech Republic
  • Research Site
    Ostrava, Czech Republic
  • Research Site
    Praha 2, Czech Republic
  • Research Site
    Praha 5, Czech Republic
  • Research Site
    Praha 8, Czech Republic
  • Research Site
    Tallinn, Estonia
  • Research Site
    Tartu, Estonia
  • Research Site
    Thessaloniki, Greece
  • Research Site
    Kochi, Kerala, India
  • Research Site
    Thiruvananthapuram, Kerala, India
  • Research Site
    Bhopal, Madhya Pradesh, India
  • Research Site
    Pune, Maharashtra, India
  • Research Site
    Ansari Nagar, New Dehli, India
  • Research Site
    Jaipur, Rajasthan, India
  • Research Site
    Kolkatta, West Bengal, India
  • Research Site
    New Dehli, India
  • Research Site
    Petach Tikva, Israel
  • Research Site
    Tel-Hashomer, Israel
  • Research Site
    Bologna, Italy
  • Research Site
    Cuneo, Italy
  • Research Site
    Forli', Italy
  • Research Site
    Genova, Italy
  • Research Site
    Milano, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Torino, Italy
  • Research Site
    Riga, Latvia
  • Research Site
    Klaipeda, Lithuania
  • Research Site
    Vilnius, Lithuania
  • Research Site
    Nilai, Malaysia
  • Research Site
    Petaling Jaya, Malaysia
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Maastricht, Netherlands
  • Research Site
    Nijmegen, Netherlands
  • Research Site
    Utrecht, Netherlands
  • Research Site
    Oslo, Norway
  • Research Site
    Krasnogorsk, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    St.Petersburg, Russian Federation
  • Research Site
    Zaloska, Ljubljana, Slovenia
  • Research Site
    Ljubljana, Slovenia
  • Research Site
    Bloemfontein, South Africa
  • Research Site
    Cape Town, South Africa
  • Research Site
    Durban, South Africa
  • Research Site
    Johannesburg, South Africa
  • Research Site
    Pretoria, South Africa
  • Research Site
    Tygerberg, South Africa
  • Research Site
    Santiago de Compostela, A Coruña, Spain
  • Research Site
    Leganés, Madrid, Spain
  • Research Site
    Baracaldo, Vizcaya, Spain
  • Research Site
    Granada, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Pontevedra, Spain

Showing the first 100 of 110 sites across 25 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003, a primary completion of Sep 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2005
First posted
Sep 21, 2005
Start
Nov 2003
Primary completionActual
Sep 2007
CompletionActual
Sep 2007
Last update
Jan 27, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00206219
Lead sponsor
AstraZeneca
First posted
Sep 21, 2005
Start date
Nov 2003
Primary completion
Sep 2007
Completion
Sep 2007
Last update
Jan 27, 2011

Study contacts

AstraZeneca Iressa Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion